Abstract

Identification of EGFR mutations is critical to the treatment of primary lung cancer and brain metastases (BMs). Here, we explored whether radiomic features of contrast-enhanced T1-weighted images (T1WIs) of BMs predict EGFR mutation status in primary lung cancer cases. In total, 1209 features were extracted from the contrast-enhanced T1WIs of 61 patients with 210 measurable BMs. Feature selection and classification were optimized using several machine learning algorithms. Ten-fold cross-validation was applied to the T1WI BM dataset (189 BMs for training and 21 BMs for the test set). Area under receiver operating characteristic curves (AUC), accuracy, sensitivity, and specificity were calculated. Subgroup analyses were also performed according to metastasis size. For all measurable BMs, random forest (RF) classification with RF selection demonstrated the highest diagnostic performance for identifying EGFR mutation (AUC: 86.81). Support vector machine and AdaBoost were comparable to RF classification. Subgroup analyses revealed that small BMs had the highest AUC (89.09). The diagnostic performance for large BMs was lower than that for small BMs (the highest AUC: 78.22). Contrast-enhanced T1-weighted image radiomics of brain metastases predicted the EGFR mutation status of lung cancer BMs with good diagnostic performance. However, further study is necessary to apply this algorithm more widely and to larger BMs.

Highlights

  • Lung cancer is one of the leading causes of cancer-related death worldwide, resulting in more than 1.18 million deaths annually[1,2,3]

  • We hypothesized that radiomics from contrast-enhanced T1-weighted images of brain metastases (BMs) could be applied to predict epidermal growth factor receptor (EGFR) mutation status in primary lung cancers

  • Majority of BMs in our cohorts were diagnosed at initial screening (48/61, 79%) and there was no significant difference between two groups (24/32, 75% vs. 24/29, 82.7%, p = 0.67)

Read more

Summary

Introduction

Lung cancer is one of the leading causes of cancer-related death worldwide, resulting in more than 1.18 million deaths annually[1,2,3]. Many www.nature.com/scientificreports recent studies have reported that patients with lung cancer and BMs harboring EGFR mutations exhibit improved survival over patients without the mutations due to higher response rates to whole-brain radiation therapy and specific chemotherapy medications. Such medications include EGFR-associated tyrosine kinase inhibitors (TKIs)[12,13,14]. We hypothesized that radiomics from contrast-enhanced T1-weighted images of BMs could be applied to predict EGFR mutation status in primary lung cancers. We extracted imaging features with first-, second, and higher-order methods and subsequently used different combinations of seven feature selection methods and four classification algorithms to identify the most robust analytic models

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call